Journal of Pharmacological and Toxicological Methods Template
Write in a clean editor, then format for Journal of Pharmacological and Toxicological Methods in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Journal of Pharmacological and Toxicological Methods format
Journal of Pharmacological and Toxicological Methods is a peer-reviewed journal published by Elsevier, covering Cardiac electrophysiology and arrhythmias, Animal testing and alternatives, Neuroscience and Neural Engineering.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Journal of Pharmacological and Toxicological Methods 12 (2023) 45–58.
Formats any DOI in Journal of Pharmacological and Toxicological Methods style. No sign-up. |
| Publishes research in | Cardiac electrophysiology and arrhythmias Animal testing and alternatives Neuroscience and Neural Engineering Receptor Mechanisms and Signaling Computational Drug Discovery Methods |
| ISSN | 1056-8719 |
| Citation impact (2-yr) | 0.86 |
| h-index | 99 |
| i10-index | 1,309 |
| Total citations | 61,251 |
| Article processing charge | $3,190 |
| Top institutions publishing here | AstraZeneca (United Kingdom) |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Journal of Pharmacological and Toxicological Methods per year
Citation impact of Journal of Pharmacological and Toxicological Methods by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Journal of Pharmacological and Toxicological Methods
The implementation of the ICH S7B and E14 guidelines has been successful in preventing the introduction of potentially torsadogenic drugs to the market, but it has also unduly constrained drug development by focusing on hERG block and QT prolongation as essential determinants of proarrhythmia risk. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative was established…